论文部分内容阅读
抑制移植排斥免疫是为了使移植器官能够在受者体内长期存活，而本文试图用强化移植排斥免疫的方法来达到抗肿瘤的目的。结果表明：在实验１中用人ｋ５６２细胞强化免疫的小鼠，其存活期为４５．４±１７．６天，显著长于对照组的２２．０±１０．１天和ＢＣＧ组的２５．０±１４．０天，在实验２中用人Ｒａｊｉ细胞或异种肿瘤ＲＡ７９５肺癌细胞、大鼠脾细胞加ＢＣＧ强化免疫的昆明系小鼠，在十天后接种Ｈ２２肝癌细胞，其存活期分别为：４０．０±７．６天，４１．９±５．４天，３９．３±７．５天及４５．０天，均显著长于对照组的２５．３±６．６天（Ｐ＜０．０４），尤以大鼠脾细胞加ＢＣＧ强化免疫的昆明系小鼠预防肿瘤的效果为好，在４５天内无１只死亡，且有５／１０的小鼠出现肿瘤消退或局限的现象。在接种Ｈ２２肝癌细胞后第４５天处死荷瘤鼠，取肝、脾及胸腺称重，各组间肝、脾及胸腺重量无统计学差别（Ｐ＞０．０５）。提示强化移植排斥免疫不影响荷瘤鼠的主要免疫器官。
Inhibition of graft rejection is to make the transplanted organ survive in the recipient for a long time. However, this article attempts to achieve the purpose of anti-tumor by the method of enhanced transplant rejection. The results showed that the mice immunized with human k562 cells in experiment 1 had a survival of 45.4 ± 17.6 days which was significantly longer than the control group of 22.0 ± 10.1 days and the BCG group of 25.0 ± Kunming mice immunized with human Raji cells or heterogeneous tumor RA795 lung cancer cells, rat spleen cells and BCG-boosted in Experiment 2 on day 14.0 were inoculated with H22 hepatoma cells ten days later with survival of 40.0 ± 7.6 days, 41.9 ± 5.4 days, 39.3 ± 7.5 days and 45.0 days, both of which were significantly longer than that of the control group (P <0.04) , Especially in Kunming mice immunized with rat splenocytes and BCG, had no effect on the prevention of tumor. None died within 45 days, and 5/10 mice showed tumor regression or confinement. The tumor-bearing mice were sacrificed on the 45th day after inoculation of H22 hepatoma cells, and the weights of liver, spleen and thymus were weighed and the weights of liver, spleen and thymus were not statistically different among the groups (P> 0.05). Prompted enhanced transplant rejection immunity does not affect the main immune organs of tumor-bearing mice.